Cancer patients who receive the targeted therapy bevacizumab (Avastin) in combination with chemotherapy are at increased risk of serious side effects that may lead to death, according to a meta-analysis of 16 clinical trials that was conducted by researchers at Stony Brook University School of Medicine in New York. The risk of fatal adverse events varied by the type of chemotherapy agents used with bevacizumab, lead author Dr. Vishal Ranpura and his colleagues reported. Read more > >
- Another Radioactive Tracer Approved for Bone Scans
- Rituximab Approved as Maintenance Therapy for Follicular Lymphoma
- FDA Investigates Breast Implants and a Rare Lymphoma
- DCTD Appoints New Chief to Monitor Clinical Trials
- NCAB Holds First Meeting of 2011
- Experts Discuss National Cancer Communications Plan
- Funding Encourages Research Collaborations in China and U.S.
- Directory of Surveillance Data for Obesity Research Available
- What You Need to Know About Booklets Updated
Selected articles from past issues of the NCI Cancer Bulletin are available in Spanish.
The NCI Cancer Bulletin is produced by the National Cancer Institute (NCI), which was established in 1937. Through basic, clinical, and population-based biomedical research and training, NCI conducts and supports research that will lead to a future in which we can identify the environmental and genetic causes of cancer, prevent cancer before it starts, identify cancers that do develop at the earliest stage, eliminate cancers through innovative treatment interventions, and biologically control those cancers that we cannot eliminate so they become manageable, chronic diseases.
For more information about cancer, call 1-800-4-CANCER or visit http://www.cancer.gov.
NCI Cancer Bulletin staff can be reached at firstname.lastname@example.org.